stocks logo

TOI

Oncology Institute Inc
$
4.100
-0.01(-0.243%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.1298
Open
4.100
VWAP
4.04
Vol
2.19M
Mkt Cap
365.86M
Low
3.960
Amount
8.84M
EV/EBITDA(TTM)
--
Total Shares
74.44M
EV
401.00M
EV/OCF(TTM)
--
P/S(TTM)
0.77
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
0.00
-100%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for The Oncology Institute, Inc. (TOI) for FY2025, with the revenue forecasts being adjusted by 1.03% over the past three months. During the same period, the stock price has changed by 54.72%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.03%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+54.72%
In Past 3 Month
3 Analyst Rating
up Image
70.73% Upside
Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image
70.73% Upside
Current: 4.100
sliders
Low
6.00
Averages
7.00
High
8.00
Noble Capital
Outperform
initiated
$8
2025-07-23
Reason
Noble Capital initiated coverage of Oncology Institute with an Outperform rating and $8 price target. The medical practice management company specializing in community-based oncology practices manages and operates oncology clinics in five states, notes the analyst, who believes that trends in cost containment "will work in TOI's favor." The firm estimates FY26 revenues of $583.4M, the analyst noted.
B. Riley
Buy
initiated
$6
2025-07-16
Reason
B. Riley initiated coverage of Oncology Institute with a Buy rating and $6 price target. The firm says Oncology Institute is one of the largest oncology specialty value-based healthcare service providers. The company's recent debt facility amendment removed a key financial overhang on the shares, the analyst tells investors in a research note.
BTIG
initiated
$7
2025-05-15
Reason
BTIG initiated coverage of Oncology Institute with a Buy rating and $7 price target. The company specializes in the treatment and management of cancer patients through a blend of both fee-for-service, capitated, and value-based-care contracts, the analyst tells investors in a research note. The firm says that with the aging of America and rising complex care cost trends amongst some health plans, especially in Medicare Advantage, fee-for-service revenue within Oncology Institute will rise through 2025. Demand for capitated and managed care, sub-contracted risk will likely increase as well, contends BTIG.

Valuation Metrics

The current forward P/E ratio for Oncology Institute Inc (TOI.O) is -11.62, compared to its 5-year average forward P/E of -5.52. For a more detailed relative valuation and DCF analysis to assess Oncology Institute Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.52
Current PE
-11.62
Overvalued PE
2.43
Undervalued PE
-13.47

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.05
Current EV/EBITDA
-61.76
Overvalued EV/EBITDA
14.09
Undervalued EV/EBITDA
-28.20

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.46
Current PS
0.78
Overvalued PS
1.14
Undervalued PS
-0.23

Financials

Annual
Quarterly
FY2025Q1
YoY :
+10.29%
104.41M
Total Revenue
FY2025Q1
YoY :
-44.85%
-9.91M
Operating Profit
FY2025Q1
YoY :
-1.53%
-19.59M
Net Income after Tax
FY2025Q1
YoY :
-4.55%
-0.21
EPS - Diluted
FY2025Q1
YoY :
-67.77%
-5.32M
Free Cash Flow
FY2025Q1
YoY :
+33.79%
14.81
Gross Profit Margin - %
FY2025Q1
YoY :
-59.40%
-4.75
FCF Margin - %
FY2025Q1
YoY :
-10.71%
-18.76
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
8.0M
USD
3
3-6
Months
5.4M
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
8
1.6M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 47487.34% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
823.3K
Volume
3
6-9
Months
1.7K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
7.0K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

TOI News & Events

Events Timeline

2025-08-13 (ET)
2025-08-13
16:47:14
New
Oncology Institute reaffirms FY25 revenue view $460M-$480M
select
2025-08-13
16:39:48
New
Oncology Institute reports Q2 EPS (15c) vs. (17c) last year
select
2025-07-14 (ET)
2025-07-14
16:16:44
Oncology Institute names Kristin England chief administrative officer
select
Sign Up For More Events

News

4.5
07-19NASDAQ.COM
Friday Sector Laggards: Hospital & Medical Practitioners, Paper & Forest Products
9.0
07-08Newsfilter
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
8.5
06-06SeekingAlpha
The Oncology Institute files for $50M common stock offering
Sign Up For More News

FAQ

arrow icon

What is Oncology Institute Inc (TOI) stock price today?

The current price of TOI is 4.1 USD — it has decreased -0.24 % in the last trading day.

arrow icon

What is Oncology Institute Inc (TOI)'s business?

arrow icon

What is the price predicton of TOI Stock?

arrow icon

What is Oncology Institute Inc (TOI)'s revenue for the last quarter?

arrow icon

What is Oncology Institute Inc (TOI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Oncology Institute Inc (TOI)'s fundamentals?

arrow icon

How many employees does Oncology Institute Inc (TOI). have?

arrow icon

What is Oncology Institute Inc (TOI) market cap?